Rafael pharmaceuticals announces ongoing successful enrollment and opening of additional sites for phase 2 clinical trial of cpi-613® (devimistat) in combination with gemcitabine and cisplatin in patients with biliary tract cancer
Cranbury, n.j., jan. 18, 2022 (globe newswire) -- rafael pharmaceuticals, inc. (“rafael” or the “company”), a company focused on the growing field of cancer metabolism-based therapeutics, today announced the ongoing successful enrollment rate of its phase 2 clinical trial for cpi-613® (devimistat) in combination with gemcitabine and cisplatin in patients with biliary tract cancer. the multicenter trial is for patients with locally advanced unresectable or metastatic biliary tract cancer who have had no prior treatment. the trial is currently open through the university of michigan health rogel cancer center as an investigator-sponsored trial. the trial is also open at fred hutchinson cancer research center and ut southwestern simmons cancer center. rafael is also launching additional sites for the trial at northwestern university lurie cancer center, uh seidman cancer center, the university of arizona cancer center, university of wisconsin carbone cancer center, vanderbilt-ingram cancer center, atlantic health system cancer care, and allegheny health network cancer institute.
RFL Ratings Summary
RFL Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission